| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formulawherein m is equal to 0, 1, 2; n is equal to 0, 1, 2, 3; each p, s, t is equal to 0 or 1; X represents CHRwherein Rrepresents hydrogen;represents -CR=C<, and then a dash line represents a bond, Rindependently represents hydrogen or C-alkyl, or wherein Rtogether with one of Ror Rforms a direct bond; Rrepresents hydrogen; Rand Rare specified in: halogen, cyano, polyhalogen-C-alkyl, C-alkyl, morpholinyl, C-alkyloxy with any of said groups is optionally and independently substituted by hydroxy, NRRwherein Rand Rare independently specified in hydrogen, C-alkylcarbonyl; or Rand Rtogether with a phenyl cycle whereto attached form a naphthaline group; or one of Ror Rhave the values specified above, and the other of Ror Rtogether with Rform a direct bond; Rrepresents hydrogen; Rand Rindependently represent hydrogen, C-alkyl, hydroxy-C-alkyl, C-alkenyl or C-alkyloxy; or Rrepresents hydrogen; when p is equal to 1, then Rrepresents hydrogen; Z represents one of the radicals presented in the patent claim. Also, the invention refers to a based pharmaceutical composition, using the compounds of formula (I) for producing the drug preparation for treating the disorders medicated by p53-MDM2 interaction for treating cancer, and to methods for producing the compounds of formula (I).EFFECT: preparing the compounds of formula (I) as p53-MDM2 interaction inhibitors.13 cl, 5 tbl, 31 ex |
